Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) disclosed a share buy-back executed on 23 March 2026. The company repurchased 150,000 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 22.24 to HKD 23.16 per share, for a total outlay of HKD 3.41 million.

Following the transaction: • Issued shares (excluding treasury stock) decreased by 0.04% to 329.25 million. • Treasury shares expanded to 7.10 million, while total issued shares remained unchanged at 336.35 million. • The volume-weighted average repurchase price stood at HKD 22.70 per share.

Buy-back capacity and mandate status: • The current mandate, approved on 30 May 2025, allows the repurchase of up to 31.96 million shares. • Cumulative buy-backs under the mandate now total 4.28 million shares, representing 1.31% of the company’s issued shares at the mandate date. • A moratorium on new share issues or treasury share disposals is in place until 22 April 2026, in accordance with Hong Kong listing rules.

Board authorization and regulatory confirmations accompany the filing, indicating full compliance with Main Board Rule 13.25A requirements.